Cancer specific promoters

Details Cancer specific promoters Cancer specific promoters

2005-04-01

2010-10-19

Lucas, Zachariah (Department: 1648)

Chemistry: molecular biology and microbiology

Vector, per se

C424S093100, C514S04400A

Reexamination Certificate

active

07816131

ABSTRACT:
The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.

REFERENCES:
patent: 6638762 (2003-10-01), Chang et al.
patent: 6716824 (2004-04-01), Brunicardi
patent: 2005/0059620 (2005-03-01), Brunicardi
patent: 2005/0118154 (2005-06-01), Hung et al.
patent: 5742198 (1998-08-01), None
patent: 1009820 (2000-06-01), None
patent: 2001218587 (2001-08-01), None
patent: WO-98/33903 (1998-08-01), None
patent: WO-98/37207 (1998-08-01), None
patent: WO-99/16787 (1999-04-01), None
patent: WO-00/26343 (2000-05-01), None
patent: WO-01/94600 (2001-12-01), None
patent: WO-02/40687 (2002-05-01), None
patent: WO-03/074692 (2003-09-01), None
patent: WO-2004/089981 (2004-10-01), None
Wang et al. J. gastrointestinal Surgery Jan. 2004, vol. 8, pp. 98-108.
Wesseling et al. (Caner Gene Therapy 2001, vol. 8, No. 12, pp. 990-996.
Taylor et al. Biochemistry, 2005, vol. 44, pp. 11269-11278.
Xu et al. BBA, 2003, vol. 162, pp. 266-271.
Yan et al. The International Journal of Biochemistry & Cell Biology, vol. 38, No. 8, pp. 1417-1428.
Tirone et al. (b). Annal of Surgery, 2000, vol. 233, No. 5, pp. 603-611.
Hajri et al. Cancer Gene Therapy Jan. 2004, vol. 11, No. 1, pp. 16-27.
Darnell et al. Molecular cell Biology, Second Edition, Published in 1990, by Scientific American Book Inc. pp. 231-238.
Wu et al. PNAS 2001, vol. 98, No. 25, pp. 14598-14600.
Donello et al. J. Virol. 1998, vol. 72 (6), pp. 5085-5092.
Sagawa et al. Cancer research 1998, vol. 54, pp. 2282-2287.
Anderson et al., “Breast cancer-specific expression of theCandida albicanscytosine deaminase gene using a transcriptional targeting approach,”Cancer Gene Therapy, 7(6): 845-852, 2000.
Bartke et al., “p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells,”Oncogene, 20: 571-580, 2001.
Bauman et al., “Differential Immunohistochemical Staining for DNA Topoisomerase II α and β in Human Tissues and for DNA Topoisomerase II β in Non-Hodgkin's Lymphomas,”Mod. Pathol., 10(3): 168-175, 1997.
Boyd et al., “Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins,”Oncogene, 11: 1921-1928, 1995.
Casey et al., “Deletional analysis of the promoter region of the human transferrin receptor gene,”Nucleic Acids Research, 16(2): 629-646, 1988.
Daniel, Peter T. et al. “Expression of the death gene bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant t-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice,”Neoplasia, 94(3): 1100-1107, 1999.
Donello et al., “Woodchuck Hepatitus Virus Contains a Tripartite Posttranscriptional Regulatory Element,”J. Virology, 72(6): 5085-5092, 1998.
Elangovan et al., “Functional dissection of the pro-apoptotic protein bik: Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death,”J. Biol. Chem., 272(39): 24494-24498, 1997.
Friedman, Debbie, et al.; Ecteinascidin-743 inhibits activated but not constitutive transcription, Cancer Research, (Jun. 2002) vol. 62, pp. 3377-3381.
Fuernkranz et al., “Differential issue localization of oviduct and erythroid transferrin receptors,”Proc. Natl. Acad. Sci. USA, 88:7505-7508, 1991.
Guillou et al., “Sertoli Cell-specific Expression of the Human Transferrin Gene: Comparison with the Liver-specific Expression,”J. Biol. Chem., 266(15): 9876-9884, 1991.
Han, Jeonghoon, et al.; induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K, Molecular and Cellular Biology (Oct. 1996), pp. 5857-5864.
Hirsch et al., “Mitogenic activation of the transferrin receptor gene promoter i modulated by inhibitors of tyrosine kinases and tyrosine phosphatases,”Recept Signal Transduct., 6(3-4): 121-9, 1996.
Hochhauser et al., “Cloning and characterization of the 5′ flanking region of the human topoisomerase II alpha gene,”J. Biol. Chem., 267(26): 18961-5, 1992.
Idzerda et al., “Expression from the Transferrin Gene Promoter in Transgenic Mice,”Mol. Cell. Biol., 9(11): 5154-5162, 1989.
Isomura et al., “The Human Cytomegalovirus Major Immediate-Early Enhancer Determines the Efficiency of Immediate-Early Gene Transcription and Viral Replication in Permissive Cells at Low Multiplicity of Infection,”Journal of Virology, 77(6): 3602-3614, 2003.
Iyer et al., “Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters,”PNAS, 98(25): 14595-14600, 2001.
Katabi et al., “Hexokinase Type II: A Novel Tumor-Specific Promoter for Gene-Targeted Therapy Differentially Expressed and Regulated in Human Cancer Cells,”Human Gene Therapy, 10: 155-164, 1999.
Kawabata, “Regulation of expression of murine transferrin receptor 2,”Blood, 98(6): 1949-1954, 2001.
Kugler et al., “Tissue-specificity of liver gene expression: a common liver-specific promoter element,”Nucleic Acids Research, 16(8): 3165-3174, 1988.
Li et al., “Enhancement ofBikAntitumor Effect byBikMutants,”Cancer Res., 63: 7630-7633, 2003.
Lu et al., “Enhanced Gene Expression in Breast Cancer Cells in Vitro and Tumors in Vivo,”Molecular Therapy, 6(6): 783-792, 2002.
Maeda et al., “A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir,”Cancer Gene Therapy, 8(11): 890-896, 2001.
Mendelzon et al., “The binding site for the liver-specific transcription factor Tf-LF1 and the TATA box of the human transferrin gene promoter are the only elements necessary to direct liver-specific transcription in vitro,”Nucleic Acids Research, 18(19): 5717-5721, 1990.
Mo et al., “Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein,”Biotechn., 25(6): 1052-7, 1998.
Panaretakis, Theocharis, et al.; Activation of bak, bax, and BH3-only proteins in the apoptotic response to doxorubicin, Journal of Bio. Chem. (Nov. 2002), vol. 277, No. 46, pp. 44317-44326.
Qiao et al., “Tumor-specific transcriptional targeting of suicide gene therapy,”Gene Therapy, 9: 168-175, 2002.
Radetzki et al., “The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines,”Oncogene, 21(2): 227-38, 2002.
Sandford et al., “Rat Cytomegalovirus Major Immediate-Early Enhancer Switching Results in Altered Growth Characteristics,”Journal of Virology, 75(11): 5076-5083, 2001.
Sato et al., “Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy,”Mol. Ther., 8(5): 726-37, 2003.
Shindelman et al., “Demonstration of the Transferrin Receptor in human breast cancer tissue. Potential marker for identifying dividing cells,”Int. J. Cancer, 27:329-334, 1981.
Shterman et al., “Comparison of Transferrin Receptors, Iron Content and Isoferritin profile in norma

Affiliated with

Also associated with

Rating

Cancer specific promoters does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer specific promoters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer specific promoters will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4170924